Lilly Receives U.S. FDA Approval of Verzenio™ (abemaciclib)
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
FDA Approves ALIQOPA (copanlisib) for Adults with Relapsed Follicular Lymphoma
Pfizer Received FDA Approval for MYLOTARG® (GEMTUZUMAB OZOGAMICIN)
FDA Approves AstraZeneca's FASLODEX® (fulvestrant) for HR+ postmenopausal women with HER2- advanced breast cancer
Follow RMOS on Twitter
What's New @ RMOS:
RMOS Sponsors Colorado Cancer Coalition Symposium. Register Today!
Did You Miss Our Symposium on Immune-Related Adverse Events (irAEs)? Get Access to the Recording!
RMOS Submits Letter Regarding Medicare Part B to Department of Health and Human Services
AstraZeneca's TAGRISSO® (osimertinib) Receives FDA Full Approval
View the RMOS 2016 Year in Review!
| ACCC Resources
| ASCO Resources
| ASCO Connection |
© Oncology State Society Network. All rights reserved.